Australien - engelska - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine, quantity: 40 mg - capsule, hard - excipient ingredients: gelatin; indigo carmine; magnesium stearate; mannitol; titanium dioxide; iron oxide yellow; butan-1-ol; shellac; iron oxide black - (1) brain tumours (primary and secondary). (2) hodgkin's disease (as secondary therapy). lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. ceenu containing combinations should be used as alternative therapy in the treatment of disseminated hodgkin's disease in patients refractory to other established treatment regimens.

Egypten - engelska - EDA (Egyptian Drug Authority)

bristol-myers squibb-egypt - capsule - 400 i.u.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - apixaban - tablet - 2.5mg

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - apixaban - tablet - 5mg

Europeiska unionen - engelska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, chronic - antivirals for systemic use - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults (see sections 4.2, 4.4 and 5.1). for hcv genotype specific activity, see sections 4.4 and 5.1.,

Europeiska unionen - engelska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - hiv infections - antivirals for systemic use - hard capsuleszerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.powder for oral solutionzerit is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. the duration of therapy with zerit should be limited to the shortest time possible.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 30mg

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 60mg

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 90mg